This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FCGR2B / Low affinity immunoglobulin gamma Fc region receptor II-b · IHC design guide
Design Immunohistochemistry for FCGR2B
Plan FCGR2B staining in paraffin sections using placental endothelial cells and lymphoid subsets as reference patterns (HPA tissue IHC). The guide covers the catalog antibody's 1:100–1:300 IHC dilution range (datasheet A01690-1) and interpretation of cytoplasmic staining (HPA tissue IHC) alongside the membrane location predicted by topology (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
FCGR2B Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasm observed in placental endothelium (HPA tissue IHC); cell membrane expected from topology (UniProt) | |
| Staining pattern | Cytoplasmic staining in placental endothelium and lymphoid subsets (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, heat-mediated (datasheet A01690-1) | |
| Positive control | Placenta+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01690-1) | |
| Caveat | Antibody may detect protein from more than one gene (HPA tissue IHC) | |
| Regulation | Expression regulator not specified (UniProt) | |
| Isoform / epitope | 5 isoforms; verify extracellular versus cytoplasmic epitope coverage (UniProt) |
Section 1
Recommended FCGR2B IHC & IF Protocols
The catalog antibody protocol uses Tris-EDTA pH 9.0 retrieval (datasheet A01690-1). Four published FCGR2B IHC protocols provide additional starting points (PMC12177957; PMC11034135; PMC8796391; PMC10821851).
| Sample | Paraffin-embedded human tonsil tissue; fixative not specified (datasheet A01690-1) |
| Fixation | Image fixative and duration unreported (datasheet A01690-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Tris-EDTA pH 9.0 (datasheet A01690-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-FCGR2B, 1:100-1:300 (datasheet A01690-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | FCGR2B-positive staining in endothelial cells of placenta (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in endothelial cells in placenta and subsets of lymphoid cells. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 for the catalog antibody (datasheet A01690-1); assess staining against appropriate tissue controls before adapting a published workflow.
Section 2
What Is the Expected FCGR2B Staining Pattern?
FCGR2B is a cell membrane receptor with an extracellular region at residues 43–217 and a cytoplasmic tail at 241–310 (UniProt P31994 topology). In paraffin tissue IHC, expect the strongest reported staining in placental endothelial cells, with weaker staining in selected hematopoietic and lymphoid cells (HPA tissue IHC). HPA describes the observed placental and lymphoid staining as cytoplasmic; its tissue profile is rated Enhanced but carries a cross-gene staining caution (HPA tissue IHC).
| Distinct staining in placental endothelial cells, with an apparent membrane edge or cytoplasmic signal. | This fits the strongest reported tissue result: High placental endothelial staining (HPA tissue IHC). A membrane edge fits receptor topology (UniProt P31994 topology), while cytoplasmic appearance fits HPA's description of its IHC images (HPA tissue IHC). Record the compartment actually seen; the two sources describe different kinds of evidence. |
| Moderate staining in selected bone marrow hematopoietic cells or lymph node, tonsil, or splenic white-pulp cells. | These are reported Medium staining populations, rather than uniformly positive compartments (HPA tissue IHC). Score the named cells or regions and compare them with adjacent unstained cells. HPA's tissue reliability is Enhanced, with medium consistency between staining and RNA data and a warning that staining may include protein from more than one gene (HPA tissue IHC). |
| Predominantly nuclear staining, especially without the expected placental endothelial signal. | A nuclear-only pattern does not match the cell membrane assignment (UniProt P31994 subcellular location) or HPA's cytoplasmic tissue description (HPA tissue IHC). Treat it as unconfirmed and inspect controls, tissue morphology, and detection background before interpreting it as FCGR2B; a nuclear signal alone cannot establish a new localisation. |
| Strong staining in adipocytes, brain glia, or glandular cells where HPA reports no detection. | HPA reports no detection in adipocytes from adipose tissue and breast, caudate glial cells, and duodenal glandular cells (HPA tissue IHC). Such staining warrants review for antibody cross-reactivity or nonspecific detection (general IHC practice). HPA also cautions that its antibody staining may represent protein from more than one gene (HPA tissue IHC). |
| Widespread, weak, featureless colour across tissue and blank areas. | A diffuse deposit cannot establish the reported cell-specific distribution (HPA tissue IHC). Compare with a no-primary control and inspect blocking, washes, and chromogen development (general IHC practice). If the deposit appears in the control, resolve the detection background before assigning any cellular staining to FCGR2B. |
💡Expected FCGR2B appearanceCall the stain consistent with the expected pattern when placental endothelial cells show the strongest interpretable signal, with selected hematopoietic or lymphoid cells showing Medium staining (HPA tissue IHC); an apparent membrane edge is compatible with receptor topology (UniProt P31994 topology), and cytoplasmic appearance is reported in tissue IHC (HPA tissue IHC). Strong nuclear-only or widespread cell-independent colour is suspect (UniProt P31994 subcellular location; general IHC practice).
| Cell compartment and assay | FCGR2B has one transmembrane segment at residues 218–240 (UniProt P31994 topology). HPA's tissue IHC description calls the observed signal cytoplasmic, whereas its ICC-IF summary says Membrane and supplies no cell-line images (HPA tissue IHC; HPA subcellular). Use tissue IHC evidence for this paraffin-section decision; the ICC-IF summary does not establish an IF result in a named cell line. |
| Tissue and cell selection | Placental endothelial cells are High; bone marrow hematopoietic cells and specified lymphoid regions are Medium (HPA tissue IHC). Lung macrophages are Low, so they offer a less conspicuous comparison (HPA tissue IHC). Specify the cell population when assessing a section: HPA also reports no detection in cerebral-cortex and colon endothelial cells (HPA tissue IHC). |
| Antibody-specific confidence | HPA lists CAB007796 as IHC Enhanced and HPA014730 as IHC Supported (HPA antibodies). Its tissue profile is also rated Enhanced, but HPA reports only medium agreement between antibody staining and RNA and warns of possible staining from more than one gene (HPA tissue IHC). Treat matching anatomy as supporting evidence, not proof of exclusive FCGR2B recognition. |
| Protein forms and assay limits | UniProt lists five FCGR2B isoforms, three N-glycosylation sites, and a signal peptide at residues 1–42 (UniProt P31994 isoforms, glycosylation, processing). These features identify potential differences among protein forms; the supplied sources do not identify the antibodies' epitopes or show how these features change paraffin IHC staining. Avoid assigning a compartment difference or failed stain to a specific isoform or modification. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in placental endothelial cells. | The expected High population is absent (HPA tissue IHC); the available evidence does not establish a target-specific fixation or retrieval cause. | Confirm that endothelial cells are present, then check positive and no-primary controls, antibody application, detection reagents, and the documented retrieval procedure (general IHC practice). Record any retrieval change as an assay adjustment, not a demonstrated FCGR2B fixation effect. |
| Only faint signal in bone marrow or lymphoid tissue. | These populations are reported Medium, below the High placental endothelial result (HPA tissue IHC). | Identify the reported hematopoietic cells or lymphoid regions before scoring (HPA tissue IHC). Compare a placental positive control and examine exposure or chromogen development within the assay's validated settings (general IHC practice); do not require every cell to stain. |
| Strong nuclear-only staining. | A nuclear-only result conflicts with the assigned cell membrane location and HPA's tissue IHC description (UniProt P31994 subcellular location; HPA tissue IHC). | Compare with a no-primary control and assess morphology and detection background (general IHC practice). Repeat with an independently validated antibody if available; HPA lists distinct IHC validation statuses for CAB007796 and HPA014730 (HPA antibodies). |
| Placenta and many HPA-negative cells stain equally strongly. | A cell-independent pattern conflicts with High placental endothelial staining and reported nondetection in several named populations (HPA tissue IHC). Cross-reactivity or nonspecific detection is possible (general IHC practice). | Score endothelial cells separately, run a no-primary control, and compare reported negative cell populations (HPA tissue IHC; general IHC practice). Interpret persistent staining cautiously because HPA warns that antibody staining may include protein from more than one gene (HPA tissue IHC). |
| Brown deposit appears throughout the section or in the no-primary control. | A signal in the no-primary control implicates the detection workflow rather than primary-antibody recognition (general IHC practice). | Review endogenous activity blocking where relevant to the chosen chromogenic system, reagent carryover, wash quality, and development time (general IHC practice). Reassess cellular localisation after background is reduced; diffuse colour alone does not reproduce HPA's described distribution (HPA tissue IHC). |
| An IF result appears inconsistent with the paraffin IHC section. | HPA's ICC-IF summary says Membrane but provides no cell-line images; tissue IHC describes cytoplasmic staining in placental endothelial and selected lymphoid cells (HPA subcellular; HPA tissue IHC). | Evaluate IF with its own controls and guide. For this paraffin IHC section, use the tissue-specific IHC pattern and document whether staining appears membranous or cytoplasmic (HPA tissue IHC; UniProt P31994 topology). Do not infer an IF protocol or a named-cell IF pattern from the supplied summary. |
Experiment evidence
IHC & IF images showing FCGR2B staining
A01690-1 · IHCImmunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was use
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000072694-FCGR2B/tissue/cerebral+cortex#imid_2089200
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000072694-FCGR2B/tissue/colon#imid_2089126
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000072694-FCGR2B/tissue/liver#imid_2089135
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000072694-FCGR2B/tissue/kidney#imid_2089128
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for FCGR2B IHC & IF
🧪Run placenta first: endothelial cells should stain strongly (HPA: High in placental endothelial cells). Use adipose tissue as a negative comparator, scoring adipocytes as unstained (HPA: Not detected in adipocytes); on the placenta slide, treat morphologically identified cells without specific staining as internal background references, without assuming every non-endothelial cell is FCGR2B-negative.
Positive control tissue: Placenta (Endothelial cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for FCGR2B; derive a cell-line control from the positive tissue's cell type (Endothelial cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control and a control immunoglobulin matched to the primary antibody’s host and class; for a monoclonal primary, match its isotype. Confirm specificity with FCGR2B knockout material or peptide competition if the immunizing peptide is available; assess endogenous peroxidase in chromogenic placenta sections and tissue autofluorescence if using IF (standard IHC/IF practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected paraffin-section caption does not state the fixative (selected-SKU caption: fixative unreported). The documented tonsil IHC condition uses Tris-EDTA at pH 9.0 for antigen retrieval and primary antibody at 1:200 overnight at 4°C (selected-SKU caption); whether retrieval is essential for FCGR2B is unreported. Frozen sections and IF cannot be judged easier from the supplied evidence; Fc-receptor binding of immunoglobulin complexes may complicate background interpretation in immune-cell-rich tissue (UniProt P31994 function and tissue specificity).
HPA tissue IHC evidence for FCGR2B
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene. Antibody staining in cells/structures not annotated, view images.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Placenta | Endothelial cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Lymph node | Non-germinal center cells | Medium | Protein (IHC) | HPA → |
| Spleen | Cells in white pulp | Medium | Protein (IHC) | HPA → |
| Tonsil | Non-germinal center cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cerebral cortex | Endothelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced FCGR2B IHC Tips
Troubleshoot FCGR2B staining in paraffin sections by checking retrieval, cell identity and subcellular pattern against the available IHC evidence.
How should I retrieve FCGR2B when paraffin-section staining is weak?
Use heat-mediated Tris-EDTA pH 9.0 retrieval for paraffin-section FCGR2B IHC (datasheet A01690-1). The documented tonsil staining used this buffer, primary antibody at 1:200 overnight at 4°C, and secondary antibody at 1:200 for 30 minutes at room temperature (caption A01690-1). If staining remains weak, compare a small retrieval-time series on adjacent sections while holding antibody and detection conditions constant (standard IHC practice). Include a known positive compartment, such as placental endothelial cells, to distinguish retrieval failure from low expression in the test area (HPA: High in placental endothelial cells). Excessive retrieval can damage morphology and complicate cell-level scoring (standard IHC practice).
Does fixation explain inconsistent FCGR2B staining between paraffin blocks?
Target-specific fixation sensitivity is unknown; the selected paraffin-section caption does not report a fixative (caption A01690-1). Compare fixation records before attributing differences between blocks to FCGR2B biology, and keep section thickness, retrieval and detection conditions matched (standard IHC practice). Where material permits, test matched samples fixed in 10% neutral buffered formalin for 6 and 24 hours as an optimisation experiment, not an established FCGR2B requirement (standard IHC practice). Run the documented Tris-EDTA pH 9.0 retrieval across that comparison (datasheet A01690-1). Judge any gain against preserved morphology and the expected cell distribution, because staining intensity alone cannot establish specificity (standard IHC practice; HPA: placental endothelial and lymphoid subsets).
Should FCGR2B appear on membranes or in cytoplasm in tissue sections?
FCGR2B is a cell-membrane receptor with an extracellular region at residues 43–217, a transmembrane segment at 218–240, and a cytoplasmic tail at 241–310 (UniProt P31994 topology). Interpret convincing chromogenic signal in identified cells alongside that membrane assignment and the HPA report of cytoplasmic staining in placental endothelial cells and lymphoid subsets (UniProt P31994 subcellular location; HPA: tissue profile). Diffuse cytoplasmic colour alone does not establish surface localisation, particularly when the catalog antibody's epitope is unspecified (standard IHC interpretation; supplied antibody evidence). Compare adjacent morphology and, if needed, a cell-type marker on serial sections before calling endothelial or lymphoid staining (standard IHC practice). Record membrane-associated and cytoplasmic patterns separately rather than collapsing them into one score (standard IHC practice).
Can this stain distinguish FCGR2B isoforms or extracellular from intracellular epitopes?
Do not assign an isoform or epitope from staining alone: the supplied catalog caption specifies no antibody epitope (caption A01690-1). FCGR2B has 5 listed isoforms, while its extracellular region spans residues 43–217 and cytoplasmic region spans 241–310 (UniProt P31994 isoforms and topology). Glycosylation at residues 106, 180 and 187, and phosphorylation at 292, identify modifications to consider when comparing candidate epitopes; they do not establish this antibody's binding site (UniProt P31994 modifications; supplied antibody evidence). Check the antibody's immunogen or mapped epitope before interpreting apparent isoform selectivity, and validate any such claim with an independent isoform-resolving method (standard IHC practice). Keep compartment and cell-type annotations separate from claims of molecular specificity (standard IHC interpretation).
How should I assess FCGR2B in multiplex tissue immunofluorescence?
For a separate IF validation, pair FCGR2B with a marker identifying placental endothelial cells or the lymphoid subset under study; those are reported IHC-positive populations (HPA: tissue profile). Choose a far-red detection channel when shorter wavelengths show tissue autofluorescence, and inspect unstained tissue in every planned channel (standard IF practice). If the antibody recognises an extracellular epitope, first assess staining without permeabilisation; an intracellular-tail epitope requires access across the membrane (UniProt P31994 topology; standard IF practice). The catalog epitope is unspecified, so compare permeabilised and unpermeabilised conditions experimentally rather than inferring access from the paraffin-section caption (caption A01690-1; standard IF practice). This IHC caption supplies no IF/ICC validation or IF protocol conditions (caption A01690-1).
How can I reduce misleading chromogenic background around FCGR2B-positive cells?
Start with an antibody-omission control and inspect whether colour persists in the same structures; persistent signal points toward the detection workflow (standard IHC practice). Block endogenous peroxidase before HRP/DAB detection, then titrate the primary around the documented 1:200 dilution while keeping exposure and development consistent (standard IHC practice; caption A01690-1). Because FCGR2B binds Fc regions of complexed IgG, assess whether immunoglobulin-based reagents contribute cell-associated background using suitable reagent controls (UniProt P31994 function; standard IHC practice). Apply a compatible protein block and wash consistently, checking that adjustments retain staining in a positive reference compartment (standard IHC practice; HPA: High in placental endothelial cells). Do not score precipitate, tissue folds or edge staining as cellular signal (standard IHC practice).
What is a defensible way to quantify FCGR2B IHC across samples? ⚠ ANSWER MARKED FOR VERIFICATION
Define the compartment and cell population before scoring; placental endothelial cells and non-germinal-center lymphoid populations have reported staining, but their intensities differ (HPA: tissue profile). For a cell-based readout, report percent positive cells and an H-score calculated as 0–300 from percentages in intensity classes 0–3 (standard IHC practice). If counting discrete positive cells, report density per mm² of viable, annotated tissue or a specified cell-rich region (standard IHC practice). Normalise each measure to the eligible cell population or region area, and use the same thresholds, counterstain and imaging settings across slides (standard IHC practice). Score membrane-associated and cytoplasmic signal separately because their interpretation differs for this membrane receptor (UniProt P31994 subcellular location; HPA: tissue profile).
When is an FCGR2B-positive chromogenic pattern convincing rather than artefactual?
A convincing result localises to identifiable cells in an expected tissue compartment and is reproducible across comparable sections (HPA: placental endothelial and lymphoid staining; standard IHC practice). Weigh membrane-associated staining against FCGR2B's assigned cell-membrane location, while recognising HPA's reported cytoplasmic pattern in placental endothelial cells and lymphoid subsets (UniProt P31994 subcellular location; HPA: tissue profile). Treat signal confined to tissue edges, folds or necrotic areas, or persisting in an antibody-omission control, as suspect (standard IHC practice). Include a peroxidase-block control if diffuse DAB colour suggests endogenous enzyme activity (standard IHC practice). HPA rates its tissue data Enhanced but warns that its antibody targets protein from more than one gene, so corroborate disputed cell-level assignments independently (HPA: reliability description).
Boster reagents
Best FCGR2B / Low affinity immunoglobulin gamma Fc region receptor II-b IHC Antibodies
A01690-1 has a human paraffin-section IHC image (catalog image caption). IF is listed without an IF image (catalog applications; image list); Human, Mouse and Rat reactivity is listed (catalog reactivity).
Real IHC data
Anti-CD32 FCGR2B Antibody
Cat # A01690-1
A01690-1 will render with its own IHC image of paraffin-embedded human tonsil, using a 1:200 primary dilution and Tris-EDTA retrieval at pH 9.0 (catalog image caption). The catalog lists IF and Human, Mouse and Rat reactivity, but provides no IF image; the IHC caption does not report the fixative (catalog applications, reactivity and image caption).
Which to pick: Choose A01690-1 for paraffin-section IHC because its own human tonsil image documents that preparation; the fixative is unreported (catalog image caption). For IF, A01690-1 lists a 1:50 dilution, but has no IF image, and ICC is not listed (catalog dilution, applications and image list). For cross-species planning, A01690-1 lists Human, Mouse and Rat reactivity; its host is Rabbit, and clonality is unreported (catalog reactivity, host and clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P31994 (FCG2B_HUMAN, Low affinity immunoglobulin gamma Fc region receptor II-b).
- Human Protein Atlas. FCGR2B tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. FCGR2B subcellular location (ICC-IF): Membrane.
- Human Protein Atlas. FCGR2B antibody validation summary (2 antibodies).
- FCGR2B knockdown alleviates diabetes-induced cognitive dysfunction by altering neuronal excitability. Molecular medicine (Cambridge, Mass.) 2025 — PMC12177957.
- Elk1 enhances inflammatory cell infiltration and exacerbates acute lung injury/acute respiratory distress syndrome by suppressing Fcgr2b transcription. Molecular medicine (Cambridge, Mass.) 2024 — PMC11034135.
- Brain macrophages acquire distinct transcriptomes in multiple sclerosis lesions and normal appearing white matter. Acta neuropathologica communications 2022 — PMC8796391.
- Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome. Cancer immunology, immunotherapy : CII 2024 — PMC10821851.
- PubMed PMID:2531080 — UniProt-cited evidence.
- PubMed PMID:2529342 — UniProt-cited evidence.
- PubMed PMID:2142460 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b). Expected localisation Cytoplasm observed in placental endothelium (HPA tissue IHC); cell membrane expected from topology (UniProt). Antigen retrieval: Tris-EDTA pH 9.0 HIER, heat-mediated (datasheet A01690-1). Validated IHC antibody: A01690-1 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Placenta (Endothelial cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human tonsil tissue; fixative not specified (datasheet A01690-1); 2. Fixation: Image fixative and duration unreported (datasheet A01690-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Tris-EDTA pH 9.0 (datasheet A01690-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-FCGR2B, 1:100-1:300 (datasheet A01690-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01690-1); Caveat: Antibody may detect protein from more than one gene (HPA tissue IHC); Isoform / epitope: 5 isoforms; verify extracellular versus cytoplasmic epitope coverage (UniProt); Regulation: Expression regulator not specified (UniProt). Evidence: UniProt P31994, HPA tissue IHC · Enhanced, HPA ICC-IF · Membrane, Datasheet A01690-1, PMC12177957, PMC11034135. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/FCGR2B/immunohistochemistry-ihc-guide.